Priority Research Papers:
RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model
Metrics: PDF 3422 views | HTML 5412 views | ?
Tae Jin Lee1, Farzin Haque2, Dan Shu2, Ji Young Yoo3, Hui Li2, Robert A. Yokel2, Craig Horbinski4, Tae Hyong Kim3,5, Sung-Hak Kim3, Chang-Hyuk Kwon3,6, Ichiro Nakano3, Balveen Kaur3, Peixuan Guo2, Carlo M. Croce1
1 Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
2 Department of Pharmaceutical Sciences, Nanobiotechnology Center, Markey Cancer Center, College of Pharmacy, University of Kentucky, Lexington, KY, USA
3 Department of Neurological Surgery, Dardinger Laboratory for Neuro-oncology and Neurosciences, The Ohio State University Medical Center, Columbus, OH, USA
4 Division of Neuropathology, Department of Pathology, University of Kentucky, Lexington, KY, USA
5 ProteomeTech Inc., Seoul, Korea
6 Neurosciences Research Program, Aurora Health Care Inc., Milwaukee, WI, USA
Carlo M. Croce, email:
Peixuan Guo, email:
Keywords: pRNA, nanoparticle, three-way junction, glioblastoma, siRNA
Received: February 14, 2015 Accepted: March 01, 2015 Published: March 23, 2015
Systemic siRNA administration to target and treat glioblastoma, one of the most deadly cancers, requires robust and efficient delivery platform without immunogenicity. Here we report newly emerged multivalent naked RNA nanoparticle (RNP) based on pRNA 3-way-junction (3WJ) from bacteriophage phi29 to target glioblastoma cells with folate (FA) ligand and deliver siRNA for gene silencing. Systemically injected FA-pRNA-3WJ RNPs successfully targeted and delivered siRNA into brain tumor cells in mice, and efficiently reduced luciferase reporter gene expression (4-fold lower than control). The FA-pRNA-3WJ RNP also can target human patient-derived glioblastoma stem cells, thought to be responsible for tumor initiation and deadly recurrence, without accumulation in adjacent normal brain cells, nor other major internal organs. This study provides possible application of pRNA-3WJ RNP for specific delivery of therapeutics such as siRNA, microRNA and/or chemotherapeutic drugs into glioblastoma cells without inflicting collateral damage to healthy tissues.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.